Pilar Lardelli

Colmenar Viejo, MD, Spain

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 12 publications

Higher antitumor activity of trabectedin in germline BRCA2 carriers with advanced breast cancer as compared to BRCA1 carriers: A subset analysis of a dedicated phase II trial.

Higher antitumor activity of trabectedin in germline BRCA2 carriers with advanced breast cancer as compared to BRCA1 carriers: A subset analysis of a dedicated phase II trial.

Journal: Breast (Edinburgh, Scotland)

Published: January 11, 2017

A phase II trial of trabectedin in triple-negative and HER2-overexpressing metastatic breast cancer.

A phase II trial of trabectedin in triple-negative and HER2-overexpressing metastatic breast cancer.

Journal: Breast cancer research and treatment

Published: December 28, 2015

Phase 2 Study of Trabectedin in Patients With Hormone Receptor-Positive, HER-2-Negative, Advanced Breast Carcinoma According to Expression of Xeroderma Pigmentosum G Gene.

Phase 2 Study of Trabectedin in Patients With Hormone Receptor-Positive, HER-2-Negative, Advanced Breast Carcinoma According to Expression of Xeroderma Pigmentosum G Gene.

Journal: Clinical breast cancer

Published: December 10, 2015

Trabectedin plus pegylated liposomal doxorubicin: retrospective analysis in heavily pretreated platinum-sensitive ovarian cancer.

Trabectedin plus pegylated liposomal doxorubicin: retrospective analysis in heavily pretreated platinum-sensitive ovarian cancer.

Journal: Tumori

Published: May 16, 2015

Activity of trabectedin in germline BRCA1/2-mutated metastatic breast cancer: results of an international first-in-class phase II study.

Activity of trabectedin in germline BRCA1/2-mutated metastatic breast cancer: results of an international first-in-class phase II study.

Journal: Annals of oncology : official journal of the European Society for Medical Oncology

Published: April 03, 2014

Randomised phase III trial of trabectedin versus doxorubicin-based chemotherapy as first-line therapy in translocation-related sarcomas.

Randomised phase III trial of trabectedin versus doxorubicin-based chemotherapy as first-line therapy in translocation-related sarcomas.

Journal: European journal of cancer (Oxford, England : 1990)

Published: December 04, 2013

A Phase II multicenter, open-label, clinical and pharmokinetic trial of PM00104 in patients with advanced Ewing Family of Tumors.

A Phase II multicenter, open-label, clinical and pharmokinetic trial of PM00104 in patients with advanced Ewing Family of Tumors.

Journal: Investigational new drugs

Published: September 09, 2013

Phase I clinical and pharmacokinetic study of trabectedin and cisplatin given every three weeks in patients with advanced solid tumors.

Phase I clinical and pharmacokinetic study of trabectedin and cisplatin given every three weeks in patients with advanced solid tumors.

Journal: Investigational new drugs

Published: January 14, 2013

A retrospective analysis of antitumour activity with trabectedin in translocation-related sarcomas.

A retrospective analysis of antitumour activity with trabectedin in translocation-related sarcomas.

Journal: European journal of cancer (Oxford, England : 1990)

Published: April 13, 2012

A comprehensive safety analysis confirms rhabdomyolysis as an uncommon adverse reaction in patients treated with trabectedin.

A comprehensive safety analysis confirms rhabdomyolysis as an uncommon adverse reaction in patients treated with trabectedin.

Journal: Cancer chemotherapy and pharmacology

Published: January 30, 2012

Trabectedin in patients with advanced non-small-cell lung cancer (NSCLC) with XPG and/or ERCC1 overexpression and BRCA1 underexpression and pretreated with platinum.

Trabectedin in patients with advanced non-small-cell lung cancer (NSCLC) with XPG and/or ERCC1 overexpression and BRCA1 underexpression and pretreated with platinum.

Journal: Lung cancer (Amsterdam, Netherlands)

Published: September 29, 2011

A phase I and pharmacokinetic study of plitidepsin in children with advanced solid tumours: an Innovative Therapies for Children with Cancer (ITCC) study.

A phase I and pharmacokinetic study of plitidepsin in children with advanced solid tumours: an Innovative Therapies for Children with Cancer (ITCC) study.

Journal: European journal of cancer (Oxford, England : 1990)

Published: September 28, 2011

Showing 1-12 of 12

Last Updated: 09/26/2026